Franchini M, Focosi D, Cruciani M, Joyner M, Pirofski L, Senefeld J
Diseases. 2024; 12(3).
PMID: 38534965
PMC: 10969279.
DOI: 10.3390/diseases12030041.
Feuth E, Nieminen V, Palomaki A, Ranti J, Sucksdorff M, Finnila T
Eur J Clin Microbiol Infect Dis. 2024; 43(4):723-734.
PMID: 38358552
PMC: 10965662.
DOI: 10.1007/s10096-024-04776-0.
Seth-Smith H, Vesenbeckh S, Egli A, Ott S
BMJ Case Rep. 2023; 16(12).
PMID: 38087481
PMC: 10728978.
DOI: 10.1136/bcr-2023-255255.
Yanagihara T, Kadowaki M, Otsuka J, Ishimatsu A, Taguchi K, Moriuchi Y
Cureus. 2023; 15(11):e48319.
PMID: 38060718
PMC: 10697834.
DOI: 10.7759/cureus.48319.
Nelson M, Manos C, Flanagan E, Prahalad S
Ther Adv Vaccines Immunother. 2023; 11:25151355231181242.
PMID: 37362155
PMC: 10285438.
DOI: 10.1177/25151355231181242.
Tecovirimat for the treatment of severe Mpox in Germany.
Hermanussen L, Brehm T, Wolf T, Boesecke C, Schlabe S, Borgans F
Infection. 2023; 51(5):1563-1568.
PMID: 37273167
PMC: 10240449.
DOI: 10.1007/s15010-023-02049-0.
Accelerating antiviral drug discovery: lessons from COVID-19.
von Delft A, Hall M, Kwong A, Purcell L, Saikatendu K, Schmitz U
Nat Rev Drug Discov. 2023; 22(7):585-603.
PMID: 37173515
PMC: 10176316.
DOI: 10.1038/s41573-023-00692-8.
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
Senefeld J, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman E
JAMA Netw Open. 2023; 6(1):e2250647.
PMID: 36633846
PMC: 9857047.
DOI: 10.1001/jamanetworkopen.2022.50647.
Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.
Shibeeb S, Ajaj I, Al-Jighefee H, Abdallah A
Hematol Rep. 2022; 14(4):377-388.
PMID: 36547236
PMC: 9778836.
DOI: 10.3390/hematolrep14040052.
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
Delgado-Fernandez M, Garcia-Gemar G, Fuentes-Lopez A, Munoz-Perez M, Oyonarte-Gomez S, Ruiz-Garcia I
Enferm Infecc Microbiol Clin (Engl Ed). 2022; 40(9):507-516.
PMID: 36336380
PMC: 9631336.
DOI: 10.1016/j.eimce.2021.01.009.
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies.
Shimizu A, Shirai I, Ogawa K, Miura A, Haruhara K, Oshiro K
Intern Med. 2022; 61(24):3703-3708.
PMID: 36171121
PMC: 9841105.
DOI: 10.2169/internalmedicine.0241-22.
COVID-19 in patients with B cell immune deficiency.
Vergidis P, Levy E, Ristagno E, Iyer V, OHoro J, Joshi A
J Immunol Methods. 2022; 510:113351.
PMID: 36087764
PMC: 9450485.
DOI: 10.1016/j.jim.2022.113351.
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.
Heyer A, Gunther T, Robitaille A, Lutgehetmann M, Addo M, Jarczak D
Cell Rep Med. 2022; 3(9):100735.
PMID: 36075217
PMC: 9378267.
DOI: 10.1016/j.xcrm.2022.100735.
High-resolution analysis of individual spike peptide-specific CD4 T-cell responses in vaccine recipients and COVID-19 patients.
Karsten H, Cords L, Westphal T, Knapp M, Brehm T, Hermanussen L
Clin Transl Immunology. 2022; 11(8):e1410.
PMID: 35957961
PMC: 9363231.
DOI: 10.1002/cti2.1410.
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F, Pinczes L, Payer E, Farkas K, Ujfalusi S, Dioszegi A
Ann Hematol. 2022; 101(10):2337-2345.
PMID: 35836007
PMC: 9282831.
DOI: 10.1007/s00277-022-04924-6.
High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4 T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19.
Cords L, Knapp M, Woost R, Schulte S, Kummer S, Ackermann C
Viruses. 2022; 14(6).
PMID: 35746736
PMC: 9228841.
DOI: 10.3390/v14061265.
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Prasad R, Srivastava S, Wang E, Liu J, Gami R, Abdelgadir A
Perm J. 2022; 26(1):123-131.
PMID: 35609158
PMC: 9126552.
DOI: 10.7812/TPP/21.035.
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.
Jiang Y, Rubin L, Peng T, Liu L, Xing X, Lazarovici P
Int J Biol Sci. 2022; 18(2):459-472.
PMID: 35002503
PMC: 8741849.
DOI: 10.7150/ijbs.59272.
SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.
Bansal N, Raturi M, Bansal Y
Transfus Clin Biol. 2022; 29(2):161-163.
PMID: 34973463
PMC: 8714679.
DOI: 10.1016/j.tracli.2021.12.006.
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y, Wardle H, Evans A, Hunter E, Marr H, Osborne W
Ann Clin Microbiol Antimicrob. 2021; 20(1):85.
PMID: 34969393
PMC: 8717300.
DOI: 10.1186/s12941-021-00491-2.
